Device Exits Can Rival Biotech, But Watch Out for the Risks
This article was originally published in Start Up
A look at recent exits challenges the widely held view that device investments have lower return potential than biotech investments. However, a close inspection of the risk/return profile reveals that device investors are taking on more risk than ever.
You may also be interested in...
A growing number of medical device companies that managed to go public over the past few years are finding their market capitalizations slipping away.
The general economic malaise closed the IPO window for medical device companies, forcing many to withdraw their public financing plans. Companies are adopting various financing and operational strategies to make a best of a bad situation.
Over the past several years, device manufacturers have introduced a number of PFO closure devices in Europe, but conducting randomized trials to gain US market approval has proven to be a much more difficult endeavor. Companies have experienced numerous delays and setbacks in both their stroke and migraine programs. The good news: setbacks for some could also boost randomized migraine studies still ongoing by other competitors in this field.